NZ514887A - IBD-associated microbial antigens and methods of using same - Google Patents

IBD-associated microbial antigens and methods of using same

Info

Publication number
NZ514887A
NZ514887A NZ514887A NZ51488700A NZ514887A NZ 514887 A NZ514887 A NZ 514887A NZ 514887 A NZ514887 A NZ 514887A NZ 51488700 A NZ51488700 A NZ 51488700A NZ 514887 A NZ514887 A NZ 514887A
Authority
NZ
New Zealand
Prior art keywords
ibd
methods
same
microbial antigens
associated microbial
Prior art date
Application number
NZ514887A
Other languages
English (en)
Inventor
Jonathan Braun
Christopher Sutton
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NZ514887A publication Critical patent/NZ514887A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ514887A 1999-04-30 2000-04-28 IBD-associated microbial antigens and methods of using same NZ514887A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/303,120 US6309643B1 (en) 1999-04-30 1999-04-30 IBD-associated microbial antigens and methods of using same
PCT/US2000/011473 WO2000066067A2 (en) 1999-04-30 2000-04-28 Ibd-associated microbial antigens and methods of using same

Publications (1)

Publication Number Publication Date
NZ514887A true NZ514887A (en) 2003-06-30

Family

ID=23170632

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514887A NZ514887A (en) 1999-04-30 2000-04-28 IBD-associated microbial antigens and methods of using same

Country Status (12)

Country Link
US (4) US6309643B1 (enExample)
EP (1) EP1187591B1 (enExample)
JP (2) JP4666772B2 (enExample)
AT (1) ATE461938T1 (enExample)
AU (1) AU767861B2 (enExample)
CA (1) CA2365898C (enExample)
DE (1) DE60044058D1 (enExample)
DK (1) DK1187591T3 (enExample)
ES (1) ES2341752T3 (enExample)
HK (1) HK1046287B (enExample)
NZ (1) NZ514887A (enExample)
WO (1) WO2000066067A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
US6821739B2 (en) * 2000-10-13 2004-11-23 The Regents Of The University Of California Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens
NZ537220A (en) * 2002-05-16 2008-06-30 Absorber Ab Method of isolating an endothelial cell and method of donor specific crossmatching
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7759079B2 (en) * 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US7873479B2 (en) * 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
CA2650973A1 (en) * 2006-05-03 2007-11-08 University Of Manitoba Microbial markers of inflammatory bowel disease
US7338135B1 (en) * 2006-08-11 2008-03-04 Hall David R Holder for a degradation assembly
US8685741B1 (en) 2007-03-07 2014-04-01 Nestec S.A. Methods for diagnosing irritable bowel syndrome
US20100129838A1 (en) * 2008-11-11 2010-05-27 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
NZ619527A (en) * 2009-04-14 2015-06-26 Nestec Sa Inflammatory bowel disease prognostics
ES2509616T3 (es) 2009-06-25 2014-10-17 Nestec S.A. Procedimientos de diagnóstico del síndrome del intestino irritable
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
MX343327B (es) 2011-02-17 2016-11-01 Nestec Sa Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
EP2710383B1 (en) 2011-05-16 2017-01-11 The University of Newcastle Performance of a biomarker panel for irritable bowel syndrome
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
CN103175971B (zh) * 2013-02-28 2016-10-05 苏州和锐医药科技有限公司 一种IgA抗体检测试剂盒
EP3654037A1 (en) 2013-12-03 2020-05-20 Prometheus Biosciences, Inc. Methods for predicting post-operative recurrence of crohn's disease
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
WO2017079653A2 (en) 2015-11-06 2017-05-11 Vetica Labs, Inc. Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124634A1 (en) * 1996-04-30 2003-07-03 University Of Guelph Novel proteins involved in the synthesis and assembly of O-antigen in pseudomonas aeruginosa
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same

Also Published As

Publication number Publication date
CA2365898C (en) 2012-03-13
US20010022971A1 (en) 2001-09-20
WO2000066067A2 (en) 2000-11-09
JP4666772B2 (ja) 2011-04-06
HK1046287B (en) 2010-10-08
ATE461938T1 (de) 2010-04-15
US6759530B2 (en) 2004-07-06
CA2365898A1 (en) 2000-11-09
EP1187591A4 (en) 2002-08-14
EP1187591A2 (en) 2002-03-20
US6309643B1 (en) 2001-10-30
JP2002542798A (ja) 2002-12-17
AU4806500A (en) 2000-11-17
US7557194B2 (en) 2009-07-07
ES2341752T3 (es) 2010-06-28
US20020115848A1 (en) 2002-08-22
HK1046287A1 (en) 2003-01-03
JP2011019515A (ja) 2011-02-03
DE60044058D1 (de) 2010-05-06
WO2000066067A3 (en) 2001-02-15
US20040197871A1 (en) 2004-10-07
AU767861B2 (en) 2003-11-27
EP1187591B1 (en) 2010-03-24
DK1187591T3 (da) 2010-06-28
US6320037B2 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
EP1187591A4 (en) MICROBIAL ANTIGENS ASSOCIATED WITH INFLAMMABLE COLON DISEASES (IBD) AND METHODS OF USE THEREOF
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CA2381770A1 (en) Human ctla-4 antibodies and their uses
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
NZ508366A (en) Neisseria meningitidis antigens and compositions
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
AU8727201A (en) Genes involved in intestinal inflammatory diseases and use thereof
ATE316577T1 (de) Das goodpasture-antigen bindende protein
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
WO2002065129A3 (en) Epitopic sequences for diagnosing infection by chlamydia trachomatis

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 28 APR 2020 BY COMPUTER PACKAGES INC.

Effective date: 20130426

EXPY Patent expired